Thursday March 12, 2026 – Omios Biologics, a biotechnology company revolutionizing cancer treatment through next-generation oncolytic virus immunotherapies and systemic gene delivery platforms, today announced the signing of a Material Transfer Agreement with the Beckman Research Institute of City of Hope. Under the agreement, City of Hope, one of the largest and most advanced cancer research and treatment organizations in the United States, will conduct advanced studies to further characteri

March 10, 2026 / Today Technomark Life Sciences and MAX BioPharma announced their collaboration in the development of MAX BioPharma's oxysterol drug candidate, Oxy210, for targeting metabolic dysfunction-associated steatohepatitis (MASH). As a strategic lead investor, Technomark is investing in MAX BioPharma by participating in its $13 million Series A raise to initiate and complete a Phase 1a/1b first-in-human study and invites aligned investors from the industry to join this opportunity. "We

March 09, 2026 -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that it has entered into an agreement with the Massachusetts General Hospital (“MGH”) for the design of a Phase 2 clinical trial eval

March 9, 2026 -- NewcelX Ltd. ("NewcelX") (Nasdaq: NCEL), a clinical-stage company advancing stem-cell-derived therapies for Type 1 Diabetes, today announced a collaborative research agreement with Eledon Pharmaceuticals, Inc. ("Eledon") (Nasdaq: ELDN), a clinical-stage immunology company with a focus on transplant medicine. The collaboration is designed to advance combination strategies integrating NewcelX's lead program, NCEL-101, with Eledon's investigational anti-CD40L monoclonal antibody,

Sinopia Biosciences, Inc., a biotechnology company advancing novel therapeutics discovered using its proprietary LEADS® (LEarn And DiScover) drug discovery platform, today announced a target discovery collaboration with Ono Pharmaceutical Co., Ltd. focused on an undisclosed group of rare metabolic disorders with significant unmet medical need. Under the agreement, Sinopia will apply its proprietary metabolomics-driven discovery platform to identify and validate novel therapeutic targets aimed a

March 2, 2026 -- Efor, a global leader specializing in quality and compliance for the Life Sciences industry, today announced the acquisition of DynamixE, Inc., a U.S.-based company recognized for its expertise in Commissioning, Qualification & Validation (CQV), process engineering, automation and digitalization for pharmaceutical and biotechnology industries. Founded in 2013, Efor has built a leading international platform dedicated to quality and compliance for Life Sciences industries. With

Combined company to operate as Candid Therapeutics, advancing a leading portfolio of T-cell engager therapeutics for autoimmune diseases Concurrent significantly oversubscribed and upsized financing of over $505 million committed by a syndicate of leading healthcare institutional investors and mutual funds expected to fund operations through 2030 Companies to hold joint conference call on March 2, 2026 at 8:30 AM ET Rallybio Corporation (Nasdaq: RLYB) ("Rallybio") and Candid Therapeutics, Inc

Asahi Kasei has signed a definitive agreement to acquire all issued shares of German-based Aicuris Anti-infective Cures for approximately €780m ($920.7m). The acquisition will expand the company’s speciality pharmaceutical platform into severe infectious diseases. Completion is expected in the first quarter of fiscal 2026, subject to customary conditions. The company anticipates the deal to positively impact operating income from fiscal 2028 onwards, after amortisation of goodwill and intangib

Quotient Sciences has extended its commercial partnership with Ipsen, focusing on the production of Sohonos (Palovarotene) for fibrodysplasia ossificans progressiva (FOP) FOP is an ultra-rare condition, impacting fewer than 1,000 people worldwide. The collaboration involves containment, specialised handling, and sustained supply of this highly potent molecule. The agreement includes Ipsen’s investment in additional equipment at Quotient Sciences’ facility in Boothwyn, Pennsylvania, US. This

Feb. 23, 2026 -- Elephas Biosciences Corporation (Elephas), a private company that has developed an innovative live tissue platform for immunotherapy response prediction, announced today a new research partnership with the University of Louisville that will evaluate the impact of a combination therapy of surgical intervention and immunotherapy in three different cancers, including colorectal, liver, and pancreatic. As part of the collaboration, the University of Louisville will be analyzing live